HER2 Status in Gastric and Gastroesophageal Carcinomas: Evaluation of Histopathological Fingings, Paired ResectionBiopsy Specimens, and the Effect of Neoadjuvant Therapy: A Single Center Study.

• DOI: 10.5152/tjg.2025.24488
• Publication Date: 2025-01-13
• Authors: Resmiye Irmak Yuz...; Özgül Sağol; Mehtat Ünlü; Merve Keskinkılıç; Serhan Derici; Hale Akpınar; Sülen Sarıoğlu
• Keywords: Single Center; Neoadjuvant Therapy

Accurately determining the human epidermal growth factor receptor 2 (HER2) status is crucial in identifying suitable candidates for targeted therapy gastric cancer, considering cost and potential side effects of anti-HER2 treatments. This study aimed to assess HER2 overexpression/amplification prevalence gastroesophageal cancer patients, its correlation with clinicopathological characteristics, consistency between biopsy radical specimens. We analyzed data from 667 specimens 600 gastric/gastroesophageal patients at Dokuz Eylül University Faculty Medicine 2012 2021. The expression amplification parameters were assessed. Furthermore, we compared concordance paired biopsy-radical when both endoscopic materials present. Additionally, before after treatment receiving neoadjuvant chemotherapy. In our study, +3 immunohistochemistry results more common junction tumors (23%). Human positivity gene found be significantly males, people over 65 years age, intestinal morphology. Overall was 95.5%. high samples holds significant importance clinical management. finding particularly noteworthy since assessment can generally conducted on small/limited routine practice. Our most extensive series Türkiye Balkans, which will shed light country's by investigating relationship carcinomas.